ILA 54.6
(0.0%)
Year | Total Liabilities | Total Liabilities Growth |
---|---|---|
2023 | 282.97 Million ILS | -0.53% |
2022 | 284.48 Million ILS | -5.94% |
2021 | 302.43 Million ILS | -3.14% |
2020 | 312.24 Million ILS | -35.47% |
2019 | 483.84 Million ILS | 6.67% |
2018 | 453.58 Million ILS | -1.66% |
2017 | 461.26 Million ILS | 32.94% |
2016 | 346.97 Million ILS | 61.82% |
2015 | 214.41 Million ILS | 0.0% |
Year | Total Liabilities | Total Liabilities Growth |
---|---|---|
2023 Q1 | 279.23 Million ILS | -1.84% |
2023 Q3 | 306.86 Million ILS | 5.03% |
2023 FY | 282.97 Million ILS | -0.53% |
2023 Q4 | 282.97 Million ILS | -7.78% |
2023 Q2 | 292.17 Million ILS | 4.63% |
2022 Q3 | 282.8 Million ILS | -3.76% |
2022 Q4 | 284.48 Million ILS | 0.59% |
2022 FY | 284.48 Million ILS | -5.94% |
2022 Q1 | 298.72 Million ILS | -1.23% |
2022 Q2 | 293.84 Million ILS | -1.63% |
2021 Q1 | 313.08 Million ILS | 0.27% |
2021 Q3 | 327.68 Million ILS | 11.5% |
2021 Q4 | 302.43 Million ILS | -7.7% |
2021 Q2 | 293.89 Million ILS | -6.13% |
2021 FY | 302.43 Million ILS | -3.14% |
2020 Q1 | 495.83 Million ILS | 2.48% |
2020 FY | 312.24 Million ILS | -35.47% |
2020 Q4 | 312.24 Million ILS | 2.66% |
2020 Q3 | 304.14 Million ILS | -10.86% |
2020 Q2 | 341.18 Million ILS | -31.19% |
2019 Q3 | 524.23 Million ILS | 6.77% |
2019 FY | 483.84 Million ILS | 6.67% |
2019 Q1 | 505.12 Million ILS | 11.36% |
2019 Q4 | 483.84 Million ILS | -7.7% |
2019 Q2 | 491.01 Million ILS | -2.79% |
2018 Q2 | 463.01 Million ILS | 2.45% |
2018 Q3 | 462.22 Million ILS | -0.17% |
2018 Q4 | 453.58 Million ILS | -1.87% |
2018 FY | 453.58 Million ILS | -1.66% |
2018 Q1 | 451.95 Million ILS | -2.02% |
2017 Q2 | 336 Million ILS | 0.0% |
2017 FY | 461.26 Million ILS | 32.94% |
2017 Q3 | 399.79 Million ILS | 18.99% |
2017 Q1 | - ILS | -100.0% |
2017 Q4 | 461.26 Million ILS | 15.37% |
2016 Q1 | - ILS | 0.0% |
2016 FY | 346.97 Million ILS | 61.82% |
2016 Q4 | 346.97 Million ILS | 0.0% |
2015 FY | 214.41 Million ILS | 0.0% |
Name | Total Liabilities | Total Liabilities Difference |
---|